Overview of the current use of levosimendan in France: a prospective observational cohort study

Annals of Intensive Care

Table 4 Multivariable analysis of outcome variables

Patient characteristics	Length of ICU stay^a		Length of hospital stay^b		In-hospital mortality
Patient characteristics	Regression coefficient	P-value	Regression coefficient	P-value	Odds ratio	95% CI
Age (10-year increment)	1.41 ± 0.43	0.001	2.14 ± 0.91	0.02	1.03	1.01–1.04
SOFA score at start of levosimendan treatment^c	0.53 ± 0.19	0.007	1.04 ± 0.38	0.006	1.01	1.004–1.02
Delay to levosimendan treatment (days)	1.08 ± 0.05	< 0.001	1.39 ± 0.11	< 0.001		NS
Dialysis prior to levosimendan treatment	11.48 ± 3.10	< 0.001		NS	1.29	1.16–1.44
Ventricular assistance prior to levosimendan treatment	4.91 ± 2.28	0.03		NS	1.13	1.05–1.23
Hypotension during levosimendan treatment		NS		NS	1.12	1.07–1.22
Inotropes at least one day during the week before and/or after starting levosimendan treatment		NS		NS	1.13	1.06–1.20
Total dose of levosimendan (mg)		NS		NS	0.99	0.98–0.99

NS non–significant
^a7% missing values
^b4.3% missing values
^c14.1% missing values imputed by the median of the observed values, which was 5. Patients less than 18 years of age were not included in this analysis